• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 8-K/A filed by Celcuity Inc.

    5/20/26 7:30:22 AM ET
    $CELC
    Medical Specialities
    Health Care
    Get the next $CELC alert in real time by email
    true 0001603454 0001603454 2026-02-11 2026-02-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K/A 

    (Amendment No. 1)

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): February 11, 2026

     

    Celcuity Inc.

    (Exact name of Registrant as Specified in its Charter)

     

    Delaware   001-38207   82-2863566

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    2800 Campus Drive, Suite 140

    Minneapolis, Minnesota 55441

    (Address of Principal Executive Offices and Zip Code)

     

    (763) 392-0123

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.001 par value per share   CELC   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

       

     

     

    EXPLANATORY NOTE

     

    Celcuity Inc. (the “Company”) is filing this Amendment No. 1 on Form 8-K/A (this “Amendment”) to supplement the information provided in the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2026. This Amendment sets forth the complete text of each amended item.

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On February 11, 2026, the Board of Directors (the “Board”) of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “N&CG Committee”), voted to increase the size of the Board from seven members to eight members and to appoint Charles (Chip) R. Romp as a new director to fill the resulting vacancy, effective immediately, for a term extending through the date of the Company’s 2026 Annual Meeting of Stockholders and the election of his successor, or his earlier death, resignation or removal. The Board determined that Mr. Romp qualifies as an independent director pursuant to the listing standards of The Nasdaq Stock Market LLC and the rules of the U.S. Securities and Exchange Commission (the “SEC”). On May 14, 2026, Mr. Romp was appointed by the Board to the Compensation Committee of the Board and the N&CG Committee, effective immediately.

     

    Mr. Romp will receive compensation for his service in accordance with the Company’s non-employee director compensation program, which currently provides for an annual cash retainer of $70,000, payable quarterly, and an annual equity award with a fair market value of $135,000, payable in the form of restricted stock, stock options, or a combination of both, at the director’s election.

     

    Upon appointment to the Board, the Company granted Mr. Romp a pro-rated annual grant of 215 shares of restricted stock under the Company’s 2017 Stock Incentive Plan, which vested in full on April 30, 2026.

     

    There are no arrangements or understandings between Mr. Romp and any other persons pursuant to which Mr. Romp was selected as a director of the Company. There are no relationships or related transactions between Mr. Romp or any member of his immediate family and the Company that would be required to be reported under Item 404(a) of Regulation S-K.

     

       

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 20, 2026

     

    CELCUITY INC.  
       
    By: /s/ Brian F. Sullivan  
      Brian F. Sullivan  
      Chief Executive Officer  

     

       

     

    Get the next $CELC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CELC

    DatePrice TargetRatingAnalyst
    5/4/2026$165.00Neutral → Buy
    H.C. Wainwright
    4/27/2026$150.00Mkt Outperform
    Citizens
    12/12/2025$126.00Overweight
    Wells Fargo
    11/18/2025$110.00Outperform
    Wolfe Research
    11/17/2025Buy → Neutral
    H.C. Wainwright
    9/22/2025$110.00Buy
    Guggenheim
    7/1/2025$30.00Buy
    Stifel
    7/22/2024$29.00Outperform
    Leerink Partners
    More analyst ratings

    $CELC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

    MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC) ("Celcuity" or the "Company"), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032 (the "Convertible Notes"). The aggregate principal amount of the offering was increased from the previously announced offering size of $400,000,000. The Company has granted the underwriters of the offering a 30-day option to purchase up to an additional $75,000,000 aggregate principal

    6/3/26 10:13:20 PM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032

    MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC) ("Celcuity" or the "Company"), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced a proposed underwritten public offering of $400,000,000 aggregate principal amount of its convertible senior notes due 2032 (the "Convertible Notes"). The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional $60,000,000 aggregate principal amount of Convertible Notes, solely to cover over-allotments, if any. The Convertible Notes will be general, unsecured, senior obligations

    6/3/26 7:19:12 AM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer

    Gedatolisib plus fulvestrant and palbociclib (the "gedatolisib-triplet") reduced the risk of disease progression or death by 50% vs. alpelisib plus fulvestrant (HR=0.50; 95% CI: 0.37–0.68; p<0.0001). Median progression-free survival ("PFS") was 11.1 months with the gedatolisib triplet versus 5.6 months with alpelisib plus fulvestrantGedatolisib plus fulvestrant (the "gedatolisib-doublet") reduced the risk of disease progression or death by 49% vs. alpelisib plus fulvestrant (HR=0.51; 95% CI: 0.33–0.79; descriptive p=0.0013). Median PFS was 11.3 months with the gedatolisib-doublet versus 5.6 months with alpelisib plus fulvestrantGedatolisib regimens demonstrated robust and durable responses:

    6/2/26 8:25:57 AM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Buller Richard E gifted 1,029 shares and received a gift of 1,029 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Celcuity Inc. (0001603454) (Issuer)

    5/20/26 4:58:24 PM ET
    $CELC
    Medical Specialities
    Health Care

    Director Dalvey David sold $3,517,000 worth of shares (25,000 units at $140.68) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Celcuity Inc. (0001603454) (Issuer)

    5/6/26 4:31:58 PM ET
    $CELC
    Medical Specialities
    Health Care

    Director Buller Richard E exercised 9,000 shares at a strike of $5.10 and sold $1,264,181 worth of shares (9,000 units at $140.46) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Celcuity Inc. (0001603454) (Issuer)

    5/6/26 4:30:28 PM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    SEC Filings

    View All

    SEC Form 424B5 filed by Celcuity Inc.

    424B5 - Celcuity Inc. (0001603454) (Filer)

    6/3/26 7:16:05 AM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Celcuity Inc. (0001603454) (Filer)

    6/2/26 8:10:25 AM ET
    $CELC
    Medical Specialities
    Health Care

    Amendment: SEC Form 8-K/A filed by Celcuity Inc.

    8-K/A - Celcuity Inc. (0001603454) (Filer)

    5/20/26 7:30:22 AM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Baker Bros. Advisors Lp bought $9,571,319 worth of shares (170,100 units at $56.27) (SEC Form 4)

    4 - Celcuity Inc. (0001603454) (Issuer)

    9/10/25 4:06:15 PM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Celcuity upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Celcuity from Neutral to Buy and set a new price target of $165.00

    5/4/26 8:30:30 AM ET
    $CELC
    Medical Specialities
    Health Care

    Citizens initiated coverage on Celcuity with a new price target

    Citizens initiated coverage of Celcuity with a rating of Mkt Outperform and set a new price target of $150.00

    4/27/26 8:34:35 AM ET
    $CELC
    Medical Specialities
    Health Care

    Wells Fargo initiated coverage on Celcuity with a new price target

    Wells Fargo initiated coverage of Celcuity with a rating of Overweight and set a new price target of $126.00

    12/12/25 8:49:57 AM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Leadership Updates

    Live Leadership Updates

    View All

    Celcuity Appoints Charles Romp to its Board of Directors

    MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles (Chip) R. Romp to its Board of Directors. Mr. Romp brings over 25 years of experience in the pharmaceutical industry to Celcuity, including leadership of sales teams and commercial organizations in the oncology setting. "Chip brings a wealth of oncology-related commercial expertise to our Board," said Brian Sullivan, Chief Executive Officer and co-founder of Celcuity. "Chip's deep experience commercializing significant oncology drugs will provide valuable insight to Celcuity as

    2/12/26 4:05:00 PM ET
    $CELC
    Medical Specialities
    Health Care

    Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

    Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

    7/8/25 10:25:00 AM ET
    $CELC
    $CTOR
    $EXEL
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Celcuity Appoints Eldon Mayer as Chief Commercial Officer

    MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer. Mr. Mayer joins Celcuity with over 30 years of biopharmaceutical commercial experience in companies ranging from early-stage biotechs to full scale pharmaceutical companies across many therapeutic areas, including oncology. "Eldon is an exceptional leader with a proven track record of building commercial organizations from the ground up to support the launch of a biotech company's first drug. His significant commercial experience at multiple bio

    2/20/24 7:05:00 AM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Financials

    Live finance-specific insights

    View All

    Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026

    MINNEAPOLIS, June 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced it will host a conference call and live webcast to review results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial on Tuesday, June 2, 2026 at 8:00 a.m. EDT / 7:00 a.m. CDT. Webcast and Conference Call Information The Celcuity management team will host a live webcast and conference call on Tuesday, June 2, 2026, at 8:00 a.m. EDT / 7:00 a.m. CDT to discuss the results from the Phase 3 VIKTORIA-1 trial. Those who would like to participat

    6/1/26 8:30:00 AM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update

     Phase 3 VIKTORIA-1 trial achieved primary endpoint with clinically meaningful improvement in progression-free survival in PIK3CA mutant cohort; detailed data for gedatolisib regimens will be presented at the 2026 ASCO Annual Meeting Phase 3 VIKTORIA-2 trial expanded to include a second study evaluating gedatolisib as first-line treatment in patients with endocrine-sensitive HR+/HER2- advanced breast cancerDevelopment of a gedatolisib formulation for subcutaneous injection underway; first patent application submitted to the U.S. Patent and Trademark OfficeManagement to host webcast and conference call today, May 14, 2026, at 4:30 p.m. EDT MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Celc

    5/14/26 4:01:00 PM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call

    MINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2026 after the market closes on Thursday, May 14, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: htt

    5/7/26 8:00:00 AM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Celcuity Inc.

    SC 13G/A - Celcuity Inc. (0001603454) (Subject)

    11/14/24 5:46:12 PM ET
    $CELC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Celcuity Inc.

    SC 13G/A - Celcuity Inc. (0001603454) (Subject)

    11/14/24 5:46:16 PM ET
    $CELC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Celcuity Inc.

    SC 13G - Celcuity Inc. (0001603454) (Subject)

    11/14/24 4:26:12 PM ET
    $CELC
    Medical Specialities
    Health Care